Adlai Nortye Group Ltd.
No trades
No trades
Compare with Adlai Nortye Group Ltd.
−0.54 USD
−35.62 M USD
5.01 M USD
54.40 M
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
Company info
Sector
CEO
Yang Lu
Website
Headquarters
Hangzhou
Founded
2018
IPO date
Sep 29, 2023
ISIN
US00704R1095
CUSIP
00704R109
FIGI
BBG01HP11SV4
Identifiers
ISIN US00704R1095
Adlai Nortye Group Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.
Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
